ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
65 hedge funds and large institutions have $126M invested in Adaptimmune Therapeutics in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
24% less capital invested
Capital invested by funds: $166M → $126M (-$39.9M)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
61% less call options, than puts
Call options by funds: $11K | Put options by funds: $28K
Holders
65
Holding in Top 10
1
Calls
$11K
Puts
$28K
Top Buyers
| 1 | +$1.25M | |
| 2 | +$964K | |
| 3 | +$723K | |
| 4 |
JPMorgan Chase & Co
New York
|
+$330K |
| 5 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$165K |
Top Sellers
| 1 | -$412K | |
| 2 | -$382K | |
| 3 | -$229K | |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$130K |
| 5 |
Goldman Sachs
New York
|
-$120K |